Successful treatment of a patient with postpartum factor VIII inhibitor with recombinant human interferon alpha 2a.
A patient who had developed a postpartum inhibitor to factor VIII and who did not respond to repeated therapy with steroid and high-dose intravenous gammaglobulin G was treated with one short course of low-dose recombinant interferon alpha 2a (rhIFN) s.c. Within 7 weeks from the start of rhIFN treatment, the inhibitor disappeared. It remains undetectable 8 months after therapy.
Schwerdtfeger
R
R
Department of Internal Medicine, Klinikum Rudolf Virchow, Freien Universität Berlin, Germany.
Hintz
G
G
Huhn
D
D
D000328:Adult; D001778:Blood Coagulation Disorders / Q000628:therapy*; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D011644:Puerperal Disorders / Q000628:therapy*; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins; D005169:Factor VIII